Retinitis Pigmentosa (RP) is the leading cause of inherited blindness in the developed world, affecting approximately 1 in 3000 individuals. Although there is currently no cure for RP, the genetic pathology has been well established. In this study, we developed a novel mouse model of RP (huRhoP347S) expressing a pathogenic human rhodopsin gene with a Pro347Ser (P347S) mutation on a rhodopsin knockout background. These mice undergo severe retinal degeneration at 1 month of age. In contrast to prior studies, this model was administered a gene therapy treatment at 19 days postnata. We evaluated several self-complementary adenoassociated virus (AAV) serotypes for photoreceptor tropism, including scAAV2/2, scAAV2/5, scAAV2/6.2 and scAAV2/9, and found that scAAV2/9 transduced photoreceptors with greater efficiency and expression than other vectors. We engineered an scAAV2/9 vector to contain a microRNA sequence specifically targeting the human rhodopsin gene and demonstrated its ability to silence rhodopsin by 60.2 ± 8.2% in vitro. In addition, we constructed an scAAV2/9 vector to contain a replacement 'codon-modified' rhodopsin transgene (RhoR2) that was resistant to degradation by the microRNA. We found that delivery of the RhoR2 by scAAV2/9 is capable of restoring vision to rhodopsin knockout mice, and rescuing our novel transgenic huRhoP347S mouse model of dominant RP. Average a-wave responses of RhoR2-injected eyes were 1.8-fold higher than those of control-injected eyes. We found that delivery of the microRNA and replacement rhodopsin in a 1:2 ratio produced an average electroretinography (ERG) a-wave response of 17.4±2.9 compared to 6.5±2.8 mV for eyes injected with negative control virus.
INTRODUCTION
Retinitis Pigmentosa (RP) is a group of retinal degenerative diseases that are characterized primarily by the loss of rod photoreceptor cells. RP is the most common cause of genetic blindness and affects approximately 1 in 3000 individuals in the United States. 1 Patients with RP experience night blindness, a progressive loss of peripheral visual fields and eventually loss of central vision as cone-cell viability is compromised by rod-cell death. 2 There is currently no cure available for RP. Recent results in phase I clinical trials have validated the safety and efficacy of vector-based gene augmentation therapies for type 2 Leber's congenital amaurosis, 3 which is responsible for approximately 6% of Leber's congenital amaurosis cases. 3, 4 In contrast to recessive diseases such as Leber's congenital amaurosis, gene therapy strategies for retinal disorders such as rhodopsin-linked autosomal dominant Retinitis Pigmentosa (adRP) have included methods of gene suppression, such as RNA interference (RNAi)-mediated decay of mutant mRNA. 5 Although earlier studies of gene suppression employing RNAi in animal models of adRP yielded mixed outcomes, later studies indicate significant promise of these strategies for the treatment of this subset of RP. While a 68% reduction in the mutant rhodopsin mRNA of P23H transgenic rats did not result in measurable anatomical or functional rescue, 6 a similar study involving suppression of the P23H-containing mRNA in transgenic mice resulted in a 33% increase in thickness of the retina. 7 Since then, RNAi-mediated reduction in photoreceptor loss has been observed in the RP10 murine model of adRP, 8 and has shown both anatomical and functional rescue of transgenic mice expressing a human rhodopsin containing the Pro347Ser (P347S) mutation, up to 10 weeks post-injection of an adenoassociated virus (AAV) expressing a short hairpin RNA (shRNA). 9 In addition to gene suppression, our group and others have been exploring a mutation-independent approach involving both gene suppression and replacement. 7, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Such an approach has been shown to provide both functional and anatomical rescue up to 20 weeks post-administration of treatment; 18 however, mice in this study were given a subretinal injection of the shRNA-and replacement rhodopsin-expressing AAVs at 5 days postnatal. Such early administration does not accurately reflect the circumstances observed in the clinic in which patients typically present symptoms for years before proper diagnosis and have lost the majority of rod photoreceptors before an interventional treatment can be considered. 19, 20 We have previously published an shRNA, RHOi2, which can induce RNAi-mediated decay of human rhodopsin in vitro in a mutation-independent manner. 13 In addition, we have engineered an RHOi2-resistant human rhodopsin (RhoR2) to replace the suppressed rhodopsin, using the degeneracy of the genetic code. While gene silencing strategies for RP have traditionally focused on RNAi by shRNAs, recent evidence suggests that microRNAbased hairpins may offer a safer and more effective alternative. [21] [22] [23] [24] [25] Efficacy of a microRNA targeting peripherin-2 has been shown after delivery to the subretinal space of wild-type mice in which 50% loss of photoreceptors is observed within 5 weeks of injection.
Mice carrying a mutant (P347S) human rhodopsin transgene on a wild-type background manifest a dominant form of RP, with progression of disease consistent with levels of transgene expression. 26 The P347S mutation in the human rhodopsin gene is of particular interest since six different mutations affecting this residue have been identified among patients with RP, and mutations at this amino-acid position in the human rhodopsin gene have been documented to cause a more severe form of RP than that found in patients with RP due to other mutations. 27, 28 In addition, patients with adRP caused by rhodopsin mutations express both a wild-type and a mutant allele, and retinal degeneration is usually slow.
In this study, we incorporated the RHOi2 sequence into a microRNA (miRhoi2) and tested the ability of miRhoi2 to suppress the expression of the P347S mutant rhodopsin in vivo, as well as replacement of the mutant rhodopsin with RhoR2. To do this, we generated a novel mouse model of RP (huRhoP347S) by breeding mice carrying a mutant (P347S) human rhodopsin transgene 26 onto a murine rhodopsin null (Rho) background. 29 We chose a rhodopsin-deficient background because mice heterozygous for rhodopsin have almost normal retinal development and function. [29] [30] [31] [32] In addition, we tested the ability of RhoR2 to rescue the Rho mice.
Recombinant AAV2/9 vectors expressing either miRhoi2 (AAV2/ 9miRhoi2) or RhoR2 (AAV2/9RhoR2) were generated. For both the huRhoP347S and Rho À mice, AAVs were injected at postnatal day 19. Retinal function was measured by electroretinography (ERG). Significant rescue of vision in both the huRhoP347S-and Rho À mouse models was observed after administration of the AAV2/ 9RhoR2. However, the level of rescue observed in huRhoP347S was not significantly augmented when AAV2/9RhoR2 was delivered in conjunction with the miRhoi2-expressing AAV2/9. These results illustrate the significant potential yet technical challenges for gene therapy of dominant retinal disorders.
RESULTS

Novel model of RP
A novel mouse model of RP was generated by breeding a rhodopsin null (Rho À ) mouse 29 with a mouse transgenic 26 for the human rhodopsin gene containing a P347S mutation. Offspringwas genotyped and those that carry the P347S human rhodopsin and are homozygous null for murine rhodopsin are henceforth indicated as huRhoP347S. At 4 weeks of age, the presence of rhodopsin was investigated in the retina of huRhoP347S mice by immunocytochemistry using an antibody (Rho4D2) that recognizes the N terminus of both human and mouse rhodopsin. As expected, rhodopsin was observed in the photoreceptor outer segments (OS) of normal (Rho þ ) mice, and was not observed in the retina of Rho À mice (Figure 1a) . In huRhoP347S mice, rhodopsin was observed in the outer nuclear layer (ONL) of the photoreceptors (Figure 1a) . That mislocalization of rhodopsin in huRhoP347S mice was due, in part, to a loss of OS was confirmed by scanning electron microscopy ( Figure 1b) . A comparison of normal (Rho þ ) and huRhoP347S mouse retina confirmed the presence of shortened OS at 4 weeks of age in huRhoP347S mice relative to Rho þ mice (Figure 1b) . To corroborate the phenotypic findings in the huRhoP347S mouse, a functional analysis (ERG) was performed at 4 weeks of age. A representative ERG is shown for each genotype in Figure 1c . ERG is the most widely used and accepted test for diagnosing patients with RP. It measures the electrical responses of various cells in the retina, including the photoreceptors, inner retinal (bipolar and amacrine) cells and the ganglion cells. A normal ERG will contain an a-wave (initial negative deflection, measured from 1-2 in Figure 1c (Rho þ )), followed by a b-wave (positive deflection, measured from 2-3 in Figure 1c (Rho þ )). The leading edge of the a-wave is produced by the photoreceptors, while the remainder of the signal is produced by a mixture of photoreceptors, bipolar, amacrine and Muller cells. The ERG can be used to measure the functionality of the rod and cone photoreceptors and can be used to detect changes in rod function early in the disease process.
While Rho À mice exhibited no a-or b-waves ( Figure 1c , middle panel), huRhoP347S mice had reduced a-and b-waves (Figure 1c , bottom panel) relative to those observed with normal C57Bl6/J (Rho þ ) mice (Figure 1c, top panel) . The huRhoP347S mice exhibited a significant 15-fold reduction in a-waves (18.8 ± 1.6 mV, Po0.0001) relative to Rho þ mice (291.1±26.0 mV; Figure 1d) . A significant threefold reduction was also observed in the b-waves of huRhoP347S mice (232.5 ± 12.7 mV, Po0.0001) relative to those of wild-type (Rho þ ) mice (646.3 ± 53.6 mV; Figure 1e ).
Degeneration of huRhoP347S retina
To examine the degeneration of the huRhoP347S mouse retina, sections through the retina were taken at three time points over a 24-week time course and stained with 4 0 ,6-diamidino-2-phenylindole (nuclear stain) to distinguish the cell bodies of the inner and outer neurons (inner, outer nuclear layer/INL, ONL). By 24 weeks of age, the ONL of the huRhoP347S retina had completely degenerated (Figure 2a) . Although an ONL is observed in the huRhoP347S mouse retina at 12 weeks of age, an ERG analysis shows complete loss of a-and b-waves at this time point (Figure 2b ). Cryosections (14 mm) transecting the retina were stained with 4 0 ,6-diamidino-2-phenylindole ( Figure 2c ) and ONL thickness measured at distances up to 2500 mm from the optic nerve head. To quantify the degeneration of the retina, ONL thickness was measured at 4, 12 and 24 weeks in Rho þ , huRhoP347S and Rho À mice (Figures 2d-f ). Values were additionally plotted as a ratio of ONL to inner nuclear layer thickness to normalize for any variability in orientation while cryosectioning (Supplementary Figure A) . At 4 weeks of age, the ONL of huRhoP347S and Rho À mice had begun to degenerate compared to Rho þ mice (Figure 2d ). The average ONL thickness was 55.8 ± 6.9 mm for Rho þ mice compared to 35.3 ± 4.1 mm for huRhoP347S and 38.2 ± 4.9 mm for Rho À mice. At 12 weeks of age, while the Rho À mice had an almost completely degenerated ONL, the huRhoP347S mice had approximately 10% of their original ONL remaining (Figure 2e ). The average ONL thickness at 12 weeks was 43.0 ± 7.4 mm for Rho þ mice compared to 7.4±1.5 mm for huRhoP347S and 3.5±1.0 mm for Rho À mice. At 24 weeks of age, the ONL of huRhoP347S mice was completely degenerated compared to the ONL of Rho þ (45.7 ± 6.1 mm) and Rho À (6.7 ± 1.9 mm) mice.
A microRNA (miRhoi2) targeting the human rhodopsin gene and codon-modified rhodopsin (RhoR2) We have previously described an shRNA, RHOi2, 13 which targets the coding sequence for amino acids 73-79 in the first exon of the human rhodopsin gene and has previously been shown to silence human rhodopsin in vitro. 13 The miRhoi2 microRNA was developed by insertion of that portion of the RHOi2 sequence homologous to codons 73-79 into the miR-155 structural sequence (Figure 3a) to allow proper processing of the premiRNA sequence. The miRhoi2 microRNA and a negative control microRNA (miNEG) were each cloned into pCAGEN (kind gift of C Cepko), a plasmid containing a chicken b-actin promoter/ cytomegalovirus (CMV) enhancer and a thymidine kinase pA signal from herpes simplex virus.
In addition, we modified a plasmid co-expressing human rhodopsin and RFP 13 to contain a P347S mutation in the rhodopsin cDNA. Gene silencing of the P347S-containing rhodopsin mRNA by miRhoi2 was subsequently assayed in vitro. The P347S rhodopsin-expressing plasmid was co-transfected with a plasmid containing either the miRhoi2 or miNEG into human embryonic A codon-modified rhodopsin (RhoR2) was generated as previously described by our group. 13 Using the degeneracy of the genetic code, a rhodopsin transgene was engineered to encode normal rhodopsin protein, while specifically altering 10 of the 21 nucleotides that encode amino acids 73-79 of human rhodopsin to confer resistance to the miRhoi2 microRNA used in this study. A plasmid co-expressing RhoR2 and RFP was transiently transfected with plasmids expressing either miRhoi2 or miNEG into HERs. Rhodopsin protein levels were assayed 72 h posttransient transfection by western blot analysis ( Figure 3d ). The expression of the replacement rhodopsin (normalized to RFP) in the miRhoi2-transfected HERs was not significantly altered from that produced by cells transfected with miNEG, (Figure 3e ) confirming resistance of the RhoR2 to miRhoi2.
AAV serotype 2/9 infects photoreceptors To identify the optimal vector for delivery of miRhoi2 and RhoR2 to photoreceptors in vivo, we injected several self-complementary AAV serotypes expressing green fluorescent protein (GFP) into the subretinal space of C57Bl6/J mice and vector tropism was determined by analysis of GFP expression in transverse sections of retina 3 weeks post-injection (Figures 4a-d) . AAV2/2 preferentially infected the retinal pigment epithelium (RPE), and a small number of photoreceptors. AAV2/5 infected the photoreceptors and RPE. AAV2/6.2 infected only the RPE, and AAV2/9 showed the strongest tropism for photoreceptor cells of all the serotypes tested. In addition to strong infectivity of the photoreceptors, AAV2/9 was capable of infecting a large portion of the retina 3 weeks post-injection as observed by retinal whole mount and sectioning (Figure 4e ). On the basis of these observations, we selected AAV2/9 as the optimal vector for gene delivery to the photoreceptors. AAV2/9 vectors expressing each of miRhoi2 (AAV2/9miRhoi2), miNEG (AAV2/9miNEG) and RhoR2 (AAV2/ 9RhoR2) were generated (Figure 4f ). The AAV2/9miRHOi2 and AAV2/9miNEG vectors also express GFP, the miRhoi2 and miNEG sequences being embedded in the 3 0 -untranslated region of the GFP mRNA (see Materials and Methods). Silver stain confirmed the presence of AAV genes VP1, VP2, VP3 in AAV2/9miRhoi2, AAV2/ 9miNEG and AAV2/9RhoR2 (Supplementary Figure B) . Electron microscopy-negative staining was used to determine ratio of empty to packaged viral particles (Supplementary Figure B) .
Rescue of Rho À mice by replacement of rhodopsin (RhoR2) Rho À mice were administered subretinal injections of a negative control virus (AAV2/9miNEG) into one eye and AAV2/9RhoR2 spiked 1:10 with AAV2/9GFP (GFP-only-expressing virus) into the contralateral eye at 19 days postnatally (P19). GFP expression was confirmed by fluorescence microscopy of retinal sections (data not shown). At 2 weeks post-injection, Rho À eyes injected with AAV2/9RhoR2 exhibited measurable ERG responses (Figure 5a ), whereas eyes of Rho À mice injected with AAV2/9miNEG did not exhibit ERG responses (Figure 5b ). Eyes of Rho À mice injected with AAV2/9RhoR2 exhibited average a-wave responses of 17.4 ± 3.2 mV (Figure 5c ) and average b-wave responses of 131.2 ± 11.1 mV (Figure 5d ). Rho À mice injected with AAV2/ 9RhoR2 were monitored 2, 4, 6 and 8 weeks post-injection by ERG. The level of rescue was consistent for the first 4 weeks postinjection, but then declined to approximately one-third the maximal response by 8 weeks post-injection (the latest time point examined; Figure 5e ).
Rescue of huRhoP347S mice by RhoR2
After confirming that the codon-modified replacement rhodopsin (RhoR2) was able to restore visual function in a Rho À mouse, we (e) Average a-and b-wave responses of AAV2/9RhoR2-and AAV2/9miNEG-injected eyes were calculated 2 weeks post-injection (***n ¼ 21, Po0.0001 (both waves)), 4 weeks post-injection (***n ¼ 9, Pp0.0002 (both waves)), 6 weeks post-injection (* , **n ¼ 9, Po0.05 (a-wave), Po0.009 (b-wave)) and 8 weeks post-injection (*n ¼ 9, Po0.05).
Novel mouse model of Retinitis Pigmentosa DL Greenwald et al weeks post-injection in AAV2/9RhoR2-injected eyes relative to those eyes injected with the control virus. At 8 weeks postinjection, the a-wave amplitudes of AAV2/9RhoR2-injected eyes were also significantly (n ¼ 8, Po0.05) increased relative to the eyes injected with the control virus.
Comparison of miRhoi2/RhoR2 combination and RhoR2 in rescue of huRhoP347S mice To ascertain the combinatorial effects of silencing the human pathogenic P347S rhodopsin using miRhoi2 and replacement with an miRhoi2-resistant rhodopsin (RhoR2), AAV2/9miRhoi2 was coinjected with AAV2/9RhoR2 into the subretinal space of huRhoP347S mice. The contralateral eye was injected with AAV2/9miNEG. Silencing of the human P347S rhodopsin by the miRhoi2 microRNA in vivo was confirmed by injecting AAV2/ 9miRhoi2 only into huRhoP347S mice at P19 and quantitation of rhodopsin mRNA levels by quantitative real-time polymerase chain reaction (qRT-PCR). We observed a significant (Po0.005) decrease in rhodopsin mRNA levels in huRhoP347S eyes injected with AAV2/9miRhoi2 relative to those injected with AAV2/9miNEG (Figure 7a ). Eyes of huRhoP347S mice injected with AAV2/ 9miRhoi2 and AAV2/9RhoR2 in a ratio of 1:1 displayed a significant (Po0.05) increase in ERG a-wave response (11.8 ± 1.0 mV) at 2 weeks post-injection relative to those injected with AAV2/9miNEG (6.0±2.8 mV; Figure 7b ). The huRhoP347S eyes injected with AAV2/9miRhoi2 and AAV2/9RhoR2 in a ratio of 1:1 displayed an ERG b-wave response of 134.7 ± 22.7 mV at 2 weeks post-injection compared to 87.8±19.7 mV for huRhoP347S eyes injected with AAV2/9miNEG (Figure 7c) .
We then altered the ratio of the codon-modified rhodopsin (AAV2/9RhoR2) to rhodopsin-targeting microRNA (AAV2/9miR-hoi2) to determine the effect on visual rescue. The huRhoP347S eyes injected with AAV2/9miRhoi2 and AAV2/9RhoR2 in a ratio of 1:2 displayed a significant (Po0.005) increase in ERG a-wave response (17.4 ± 2.9 mV) at 2 weeks post-injection compared with huRhoP347S eyes injected with AAV2/9miNEG (6.5±2.8 mV; Figure 7d ). The huRhoP347S eyes injected with AAV2/9miRhoi2 and AAV2/9RhoR2 in a ratio of 1:2 also displayed a significant increase (Po0.05) in ERG b-wave response (173.5±21.7 mV) at 2 weeks post-injection compared with huRhoP347S eyes injected with AAV2/9miNEG (133.7 ± 29.8 mV; Figure 7e ). The huRhoP347S eyes injected with AAV2/9miRhoi2 and AAV2/9RhoR2 in a ratio of 2:1 displayed an ERG a-wave response of 13.3 ± 3.8 mV 2 weeks post-injection compared with 11.3±2.7 mV for huRhoP347S eyes injected with AAV2/9miNEG (Figure 7f ). The huRhoP347S eyes injected with AAV2/9miRhoi2 and AAV2/9RhoR2 in a ratio of 2:1 showed no increase in ERG b-wave response (177.0 ± 30.6 mV) at 2 weeks post-injection relative to huRhoP347S eyes injected with AAV2/9miNEG (168.7 ± 32.5 mV; Figure 7g) .
When the ERG a-wave response of huRhoP347S eyes injected with AAV2/9RhoR2 alone (Figure 6c ) was compared with those of huRhoP347S eyes injected with AAV2/9miRhoi2 and AAV2/9RhoR2 in a ratio of 1:2 (Figure 7d ), no significant difference was observed (Figure 7h ).
DISCUSSION
In this study, we generated a novel mouse model of RP by breeding a rhodopsin knockout (Rho À ) mouse with a mouse containing one copy of the human rhodopsin gene containing a P347S mutation (huRhoP347S). We considered that generation of a mouse transgenic for a mutant human rhodopsin gene on a mouse rhodopsin-deficient background was necessary to test a combination of mutation-independent gene silencing and replacement with a resistant rhodopsin; previous studies have shown that mice heterozygous for rhodopsin have almost normal retinal development and function. [29] [30] [31] [32] The huRhoP347S mice present with a gradual loss of ERG responses and ONL thickness over the course of 1-3 months. Although rhodopsin was observed in the photoreceptors of huRhoP347S mice, it was confined to the ONL (Figure 1a ). This could be due to a reduction in the length of the OS and/or inefficient trafficking of rhodopsin; the P347S mutation occurs within the C terminus of rhodopsin, a region implicated in regulating the trafficking of the protein to the OS by binding to ADP-ribosylation factor 4. 35 However, that the P347S rhodopsin is functional is evidenced by measurable ERG responses in the huRhoP347S mice.
The presence of OS and measurable ERGs at 1 month of age encouraged us to administer gene therapy at P19, an age at which the retina is no longer undergoing development, eyes are opened and mice are ready to be weaned from their mother. Therapeutic intervention at this age more accurately reflects the potential clinical situation than has been the case in other studies of gene silencing using mouse models of dominant RP, which have been performed within 5 days postnatal. In addition, this model does not require a significantly long period of time to demonstrate degeneration-making the impact of therapeutic intervention more rapidly determinable.
The aim of this study was to investigate the efficiency of gene silencing using a microRNA in combination with gene replacement in an adRP mouse model. To do this, we designed a microRNA (miRhoi2) sequence that specifically and robustly silenced the pathogenic human rhodopsin gene, and a replacement rhodopsin that was codon-modified to be resistant to this microRNA while still encoding a functional human rhodopsin protein (RhoR2). We first confirmed the functionality of RhoR2 through delivery into the subretinal space of Rho À mice using AAV2/9. When administered as late as P19, the replacement rhodopsin was able to provide rescue of visual function as measured by ERG to Rho À mice. The observed functional rescue reached a maximum at 4 weeks post subretinal injection and then declined to a lower level of rescue for the remaining 4 weeks of the experimental time course. This may be due to loss of expression from the specific AAV serotype used (see below), or due to insufficient photoreceptor transduction. Administration of rhodopsin replacement via AAV2/5 at a much earlier time point, P0, has been shown to provide functional rescue of Rho À mice out to 12 weeks. 17 Others have reported longer-term (21 weeks) rescue of a photoreceptor-specific deficiency with AAV2/8; 36 however, in this case untreated mice express low levels of the implicated protein (Aipl1). Consistent with this, we did observe functional rescue of huRhoP347S, which expresses a mutant but functional rhodopsin, out to 8 weeks post-injection when augmented with AAV2/9RhoR2 at P19.
Given that the P347S allele used in this study is a dominant mutation on a normal mouse rhodopsin background, 26 we expected the P347S allele to have a dominant-negative effect on RhoR2 and limit the extent of rescue observed. The magnitude of rescue therefore would be expected to be greater when replacement rhodopsin is co-delivered with the rhodopsintargeting microRNA (miRhoi2). Several ratios of AAV2/9miRhoi2 to AAV2/9RhoR2 were investigated in this study to test the effect of gene suppression and replacement. The most efficient rescue was observed when a ratio of 1 miRhoi2 virus particle per 2 RhoR2 virus particles was administered. However, the degree of visual rescue observed at 2 weeks post-injection under this paradigm was not significantly greater than that achieved through administration of AAV2/9RhoR2 alone.
The results from the 2:1 ratio of AAV2/9miRhoi2:AAV2/9RhoR2 suggest that there is a critical threshold of replacement rhodopsin required for physiological rescue as the 1:2 and 1:1 ratios (AAV2/ 9miRhoi2:AAV2/9RhoR2) provided significantly increased visual function relative to control-injected. This is not unexpected considering that silencing of P347S rhodopsin would not be expected to restore visual function to huRhoP347S mice without replacement with functional rhodopsin.
The threshold of replacement rhodopsin required to permit functional rescue of the huRhoP347S mouse, prevented increasing the amount of miRhoi2-containing virus to have a significant additional effect on rescue. While we validated the efficacy of miRhoi2 to suppress expression of P347S rhodopsin in vivo, one possibility as to why we did not observe an enhanced rescue when co-delivered with the RhoR2-containing virus in vivo may be due to the two-virus approach in which the miRhoi2 and RhoR2 were delivered in separate viral vectors. This permits the possibility that certain photoreceptors were transduced with only one of the two viruses, in which case photoreceptors receiving only AAV2/9miRhoi2 would exhibit a decrease in visual function and photoreceptors receiving only AAV2/9RhoR2 would not exhibit visual rescue beyond that observed in the AAV2/9RhoR2-treated eyes. We chose the two-vector approach to ascertain the combinatorial effects of microRNA suppression and gene replacement; however, one could imagine a single vector approach in which miRhoi2 would be incorporated into the 3 0 -untranslated region of the replacement rhodopsin, instead of GFP as was carried out in this study, to generate an AAV co-expressing RhoR2 and miRhoi2. A number of gene silencing studies have been performed by other groups on mice transgenic for either P23H or P347S rhodopsin. Interestingly, rats carrying a transgene for P23H on a normal rat rhodopsin background exhibited no rescue when administered an AAV-expressing an shRNA targeting the mutant rhodopsin mRNA, despite significant silencing of the mutant transgene expression. 6 In another study, anatomical rescue only was observed in a mouse carrying a P23H rhodopsin and heterozygous for the endogenous wild-type rhodopsin gene; 7 in this case, mice were administered both an shRNA-expressing AAV and an AAV expressing the shRNA-resistant rhodopsin at P10. Rescue of a P347S transgenic mouse has been observed out to 20 weeks post-injection following gene suppression and replacement administered at P5, but unlike our model the mouse used in this study was heterozygous for normal mouse rhodopsin. 18 In addition, while all of the above studies utilized AAV2/5 vectors, we observed more efficient transduction of photoreceptors in vivo using self-complementary AAV2/9 vectors relative to AAV2/5. 6, 7, 18, 34, 37 The high level of photoreceptor transduction observed with AAV2/9 in our study is consistent with that observed by Lei et al. 38 when GFP expression was assayed within weeks of injection. However, a study of AAV2/9 retinal transduction in which GFP expression was assessed 6 months after injection showed no evidence of photoreceptor transduction at this later time point; 39 this could potentially explain the shortterm rescue observed in our study.
The results of this study have implications for potential treatment designs for dominant RP as well as other genetic disorders that are candidates for RNAi-based therapies.
MATERIALS AND METHODS
Transgenic mice
The huRhoP347S mice were generated by breeding mice carrying a mutant (P347S) human rhodopsin transgene 26 onto a Rho À background. 29 The P347S allele is expressed at a ratio of 0.25:1 relative to endogenous opsin mRNA. Mice were genotyped by PCR using primers specific for the neomycin resistance gene, NE04 (5 0 -CGGGAGCGGCGATA CCGTAAAGC-3 0 ) and NE07 (5 0 -GAAGCGGGAAGGGACTGGCTGCTA-3 0 ); the mouse rhodopsin gene using the primers W11 (5 0 -GTGCCTGTGATCACAGC ACTT-3 0 ) and W75 (5 0 -AGACTCACATGGGGAGGAATTC-3 0 ); 33 and the human rhodopsin gene using the primers K296EF2 (5 0 -TGACCATCCCAGCGTTCTT TG-3 0 ) and K296ER2 (5 0 -CATTTCTCACACACTCCCCATTG-3 0 ). Genotyping was performed by Transnetyx, Inc. (www.transnetyx.com).
MicroRNA design
We have previously described an shRNA, RHOi2, 13 specifically targeting the human rhodopsin gene that has been shown to silence rhodopsin in vitro. The microRNA based on this sequence, miRhoi2, was developed by insertion of that portion of the shRNA homologous to codons 73-79 of human rhodopsin into the miR-155 sequence of pcDNA6.2GW/EmGFP-miR using the BLOCK-iT Pol II miR RNAi Expression Vector Kits (Invitrogen, Carlsbad, CA, USA) and oligonucleotides mRHOi2F (5 0 -TGCTGTAGGTTGAGC AGGATGTAGTTGTTTTGGCCACTGACTGACAACTACATTGCTCAACCTA-3 0 ) and mRHOi2R (5 0 -CCTGTAGGTTGAGCAATGTAGTTGTCAGTCAGTGGCCAAAACAA CTACATCCTGCTCAACCTAC-3 0 ). As a negative control, we utilized a sequence that can form a pre-miRNA hairpin structure, but is not predicted to target any known vertebrate gene (Invitrogen). The sequence of the miNEG control microRNA is 5 0 -GAAATGTACTGCGCGTGGAGACGTTTTGGCCACTGACTGACGTCTCCACGCA GTACATTT-3 0 .
Codon-modified rhodopsin
The codon-modified rhodopsin (RhoR2) has previously been described by our group. 13 Briefly, the degeneracy of the genetic code was used to construct a rhodopsin transgene that would code for a normal rhodopsin protein via a codon-modified RNA. Of the 21 nucleotides, 10 encoding Novel mouse model of Retinitis Pigmentosa DL Greenwald et al amino acids 73-79 of human rhodopsin, which had been altered to confer resistance to the shRNA, RHOi2, would also confer resistance to the miRhoi2 microRNA used in this study. Specifically, nucleotide 793 of the rhodopsin cDNA was changed from T to C, 796 was changed from T to C, 799 and 800 were changed from T to C, 802 was changed from A to G, 803 was changed from T to C, 805 was changed from G to C, 808 and 809 were changed from T to C and 811 was changed from G to A.
P347S rhodopsin
A previously published 13 dual CMV immediate-early promoter plasmid expressing both red fluorescent protein (RFP) and the human rhodopsin cDNA (pCMVRhoRFP) was modified by site-directed PCR to contain the P347S mutation. The nucleotides CCG (Pro) were modified using site-directed mutagenesis to TCG (Ser) using the primers P347SF (5 0 -AC CACACAGAAGGCAGAGAAGGAG-3 0 ) and P347SR (5 0 -GGTGGCCTCGGCCT AAGACCTGCCTAGGATCCGGGG-3 0 ). This design incorporated a novel BamHI restriction site into the PCR product, which was then cloned into the pCMVRhoRFP plasmid by digestion with BstEII and BamHI.
Western blot analysis
Western blots were performed using standard procedures. In brief, 12.5% polyacrylamide criterion zymogram precast gels were purchased from BioRad (Hercules, CA, USA), and protein signals were detected using SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Waltham, MA, USA). Protein signals were quantified using Universal Hood II (BioRad), and software from Quantity One (version 4.5.0). Mouse monoclonal antibody Rho 1D4 was used against the C terminus and Rho4D2 against the N terminus of rhodopsin at a concentration of 1:500 (both antibodies courtesy Professor R Molday, University of British Columbia, Vancouver, BC, Canada). All western blots were analyzed by averaging the pixel intensity relative to control on four different exposures. Representative blots are shown.
AAV production AAV vectors were produced by the UMass Vector Core facility (Worcester, MA, USA). A pseudotyping strategy was used to produce AAV vectors packaged with AAV2, AAV5, AAV6.2 and AAV9 capsid proteins. Recombinant AAV genomes containing AAV2 inverted terminal repeats were packaged by triple transfection of 293 cells with cis-plasmid, adenovirus helper plasmid and a chimeric packaging construct, in which the AAV2 replication gene is fused with capsid genes of novel AAV serotypes. All recombinant vectors were purified by standard CsCl 2 sedimentation. Genome copy titers of AAV vectors were determined by TaqMan (Applied Biosystems, Foster City, CA, USA) analysis using probes and primers targeting the SV40 poly(A) region. Ratios of packaged versus unpackaged virions were determined by transmission electron microscopy (data not shown). Self-complementary AAV vectors containing the rhodopsin-targeting microRNA (AAV2/9miRhoi2), negative control microRNA (AAV2/9miNEG) and replacement rhodopsin (AAV2/9RhoR2) were generated using AAV9 capsid genes (Figure 4f ). The microRNA-expressing viruses also express EmGFP, an emerald GFP, which is co-expressed with the microRNA as part of the Invitrogen BLOCK-iT Pol II miR RNAi Expression Vector system.
Subretinal AAV injections
All experiments involving animals were performed in accordance with the Statement for the Use of Animals in Ophthalmic and Vision Research, set out by the Association for Research in Vision and Ophthalmology. Mice were anesthetized by intraperitoneal injection of xylazine (Xyla-Ject; Phoenix Pharmaceutical Inc., St Joseph, MO, USA; 10 mg ml À 1 )/ketamine HCl (Ketaset; Fort Dodge Animal Health, Fort Dodge, IA, USA; 1 mg ml À 1 ). Subretinal injections containing 1 ml of virus at a concentration of 5 Â 10 9 virus particles per microliter were performed with a 32-G needle (Becton Dickinson, Franklin Lakes, NJ, USA) and a 5 ml glass syringe (Hamilton, Reno, NV, USA) by a trans-scleral trans-choroidal approach. Animals were killed by CO 2 inhalation followed by cervical dislocation.
qRT-PCR Rhodopsin gene expression was measured by qRT-PCR using a commercially available primer/probe reagent. A measure of 1 ml of AAV2/9miRhoi2, AAV2/9miNEG or AAV2/9RhoR2 was subretinally injected into Rho À or P347S mice 19 days postnatal. Mice were killed 3 weeks post-injection, and sections of retina expressing GFP were isolated. Retinal tissue was then homogenized and total mRNA was extracted using QIAGEN total RNA kit. RNA (1.5 mg) was treated with Turbo DNAse (Ambion, Foster City, CA, USA) for 1 h at 371C, and DNAse inactivation reagent for 5 min before qRT-PCR reaction. A measure of 3.5 ml of mRNA was used in a standard one-step qRT-PCR protocol measuring human rhodopsin mRNA (Hs00173452_m1 Rho; Applied Biosystems) and was normalized to mouse b-actin (Applied Biosystems). All experiments were performed in quadruplicate using Bio-Rad iQ5 Multicolor real-time PCR detection system.
Electroretinography
Animals were dark adapted overnight and all procedures were carried out under dim red light. To anesthetize the animals, ketamine and xylazine were injected intraperitoneally as described above. Pupils were dilated with 2.5% phenylephrine hydrochloride ophthalmic solution USP (Bausch & Lomb, Tampa, FL, USA) and 1% tropicamide (Akorn Inc., Lake Forest, IL, USA). Eyes were maintained in a proptosed position throughout the examination. Reference and ground electrodes were positioned subcutaneously, B1 mm from the temporal canthus and anterior to the tail, respectively. ERG responses were recorded simultaneously from both eyes by means of gold wire electrodes, which were positioned to touch the central cornea of each eye. Corneal hydration was maintained after the examination by the application of phosphate-buffered saline to the cornea. Scotopic electroretinograms were recorded at a flash intensity of À 10 dB using contact lens electrodes and the UTAS system with BigShot ganzfeld (LKC Technologies Inc., Gaithersburg, MD, USA). In all, 10 flashes were averaged for each recording. ERG results were analyzed using standard statistical convention (paired Student's t-test) and represented as mean absolute values and standard error (s.e.).
